Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Net Income towards Common Stockholders: 2018-2024

Historic Net Income towards Common Stockholders for Eton Pharmaceuticals (ETON) over the last 7 years, with Dec 2024 value amounting to -$3.8 million.

  • Eton Pharmaceuticals' Net Income towards Common Stockholders fell 407.34% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.7 million, marking a year-over-year decrease of 21.91%. This contributed to the annual value of -$3.8 million for FY2024, which is 308.44% down from last year.
  • According to the latest figures from FY2024, Eton Pharmaceuticals' Net Income towards Common Stockholders is -$3.8 million, which was down 308.44% from -$936,000 recorded in FY2023.
  • Eton Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at -$936,000 for FY2023, and its period low was -$28.0 million during FY2020.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$3.8 million (2024), whereas its average is -$4.6 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first soared by 93.01% in 2021, then tumbled by 361.43% in 2022.
  • Eton Pharmaceuticals' Net Income towards Common Stockholders (MRY) stood at -$28.0 million in 2020, then soared by 93.01% to -$2.0 million in 2021, then plummeted by 361.43% to -$9.0 million in 2022, then surged by 89.62% to -$936,000 in 2023, then crashed by 308.44% to -$3.8 million in 2024.
  • Its Net Income towards Common Stockholders stands at -$3.8 million for FY2024, versus -$936,000 for FY2023 and -$9.0 million for FY2022.